Celularity Forms Strategic Partnership with NEXGEL
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy NXGL?
Source: Globenewswire
- Strategic Partnership: Celularity's strategic commercialization partnership with NEXGEL aims to leverage renewed regulatory and reimbursement clarity to rapidly enhance market share, with the transaction expected to close by April 15, 2026, marking a significant collaboration in the biomaterials sector.
- Enhanced Production Capacity: Celularity will exclusively manufacture these biomaterial products at its FDA-compliant facility in Florham Park, New Jersey, utilizing its vertically integrated manufacturing infrastructure designed to support scalable, quality-driven production, which is expected to significantly enhance product competitiveness in the market.
- Market Potential: The partnership involves established products like Biovance and Natalin, as well as potential disruptors such as SPARK, FUSE, and ORCHID, which are anticipated to generate substantial milestone payments and manufacturing revenues for Celularity, further solidifying its leadership in regenerative medicine.
- Focus on Core Competencies: CEO Robert J. Hariri emphasized that this partnership allows Celularity to concentrate on its core strength—contract manufacturing—expected to achieve cost efficiencies through effective biomaterial production, thereby driving growth in the biomaterials market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NXGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NXGL
About NXGL
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises CG Converting and Packaging, LLC (CGN), a joint venture with C.G. Laboratories Inc. (CG Labs) used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NEXGEL Schedules Q4 and FY 2025 Earnings Call
- Earnings Release Schedule: NEXGEL will report its financial results for the fiscal year 2025 and Q4 on March 31, 2026, after market close, reflecting the company's ongoing commitment to transparency and investor communication.
- Conference Call Timing: Following the earnings release, the company will host a conference call at 4:30 PM ET on the same day, providing investors with a direct opportunity to engage with management and enhance market confidence in the company's future prospects.
- Replay Availability: For investors unable to attend the live call, NEXGEL offers a replay service available until April 14, 2026, ensuring all stakeholders can access critical information, thereby improving information accessibility.
- Company Background: NEXGEL specializes in healthcare, beauty, and OTC products, with over two decades of experience in developing electron-beam cross-linked hydrogels, showcasing its leadership position and technological expertise in the industry.
See More
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
See More
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
See More
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
See More
Celularity Forms Strategic Partnership with NEXGEL
- Strategic Partnership: Celularity's strategic commercialization partnership with NEXGEL aims to leverage renewed regulatory and reimbursement clarity to rapidly enhance market share, with the transaction expected to close by April 15, 2026, marking a significant collaboration in the biomaterials sector.
- Enhanced Production Capacity: Celularity will exclusively manufacture these biomaterial products at its FDA-compliant facility in Florham Park, New Jersey, utilizing its vertically integrated manufacturing infrastructure designed to support scalable, quality-driven production, which is expected to significantly enhance product competitiveness in the market.
- Market Potential: The partnership involves established products like Biovance and Natalin, as well as potential disruptors such as SPARK, FUSE, and ORCHID, which are anticipated to generate substantial milestone payments and manufacturing revenues for Celularity, further solidifying its leadership in regenerative medicine.
- Focus on Core Competencies: CEO Robert J. Hariri emphasized that this partnership allows Celularity to concentrate on its core strength—contract manufacturing—expected to achieve cost efficiencies through effective biomaterial production, thereby driving growth in the biomaterials market.
See More
NexGel Expects Revenue to Triple
- Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
- Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
- Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
- Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.
See More
NEXGEL Schedules Q4 and FY 2025 Earnings Call
- Earnings Release Schedule: NEXGEL will report its financial results for the fiscal year 2025 and Q4 on March 31, 2026, after market close, reflecting the company's ongoing commitment to transparency and investor communication.
- Conference Call Timing: Following the earnings release, the company will host a conference call at 4:30 PM ET on the same day, providing investors with a direct opportunity to engage with management and enhance market confidence in the company's future prospects.
- Replay Availability: For investors unable to attend the live call, NEXGEL offers a replay service available until April 14, 2026, ensuring all stakeholders can access critical information, thereby improving information accessibility.
- Company Background: NEXGEL specializes in healthcare, beauty, and OTC products, with over two decades of experience in developing electron-beam cross-linked hydrogels, showcasing its leadership position and technological expertise in the industry.
See More
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
See More
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
See More
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
See More
Celularity Forms Strategic Partnership with NEXGEL
- Strategic Partnership: Celularity's strategic commercialization partnership with NEXGEL aims to leverage renewed regulatory and reimbursement clarity to rapidly enhance market share, with the transaction expected to close by April 15, 2026, marking a significant collaboration in the biomaterials sector.
- Enhanced Production Capacity: Celularity will exclusively manufacture these biomaterial products at its FDA-compliant facility in Florham Park, New Jersey, utilizing its vertically integrated manufacturing infrastructure designed to support scalable, quality-driven production, which is expected to significantly enhance product competitiveness in the market.
- Market Potential: The partnership involves established products like Biovance and Natalin, as well as potential disruptors such as SPARK, FUSE, and ORCHID, which are anticipated to generate substantial milestone payments and manufacturing revenues for Celularity, further solidifying its leadership in regenerative medicine.
- Focus on Core Competencies: CEO Robert J. Hariri emphasized that this partnership allows Celularity to concentrate on its core strength—contract manufacturing—expected to achieve cost efficiencies through effective biomaterial production, thereby driving growth in the biomaterials market.
See More
NexGel Expects Revenue to Triple
- Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
- Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
- Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
- Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.
See More
